Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Department of Internal Medicine, Boston Medical Center, Boston, Massachusetts.
JAMA Intern Med. 2015 Dec;175(12):1955-9. doi: 10.1001/jamainternmed.2015.5610.
Although insider trading is illegal, recent high-profile cases have involved physicians and scientists who are part of corporate governance or who have access to information about clinical trials of investigational products. Insider trading occurs when a person in possession of information that might affect the share price of a company's stock uses that information to buy or sell securities--or supplies that information to others who buy or sell--when the person is expected to keep such information confidential. The input that physicians and scientists provide to business leaders can serve legitimate social functions, but insider trading threatens to undermine any positive outcomes of these relationships. We review insider-trading rules and consider approaches to securities fraud in the health care field. Given the magnitude of the potential financial rewards, the ease of concealing illegal conduct, and the absence of identifiable victims, the temptation for physicians and scientists to engage in insider trading will always be present. Minimizing the occurrence of insider trading will require robust education, strictly enforced contractual provisions, and selective prohibitions against high-risk conduct, such as participation in expert consulting networks and online physician forums, by those individuals with access to valuable inside information.
尽管内幕交易是非法的,但最近一些备受瞩目的案件涉及到参与公司治理的医生和科学家,或者他们可以获得有关研究产品临床试验的信息。内幕交易是指当一个人拥有可能影响公司股票价格的信息时,他利用这些信息买卖证券,或者向买卖证券的其他人提供这些信息,而这个人预计会对这些信息保密。医生和科学家向商业领袖提供的信息可以发挥合法的社会功能,但内幕交易有可能破坏这些关系的任何积极成果。我们审查了内幕交易规则,并考虑了医疗保健领域的证券欺诈问题。鉴于潜在财务回报的巨大、隐藏非法行为的容易程度以及没有可识别的受害者,医生和科学家进行内幕交易的诱惑将始终存在。要减少内幕交易的发生,需要进行强有力的教育,严格执行合同条款,并对那些有机会接触到有价值内幕信息的人,选择性地禁止他们参与高风险行为,如参与专家咨询网络和在线医生论坛。